Literature DB >> 26054687

Sirtuin-4 (SIRT4) is downregulated and associated with some clinicopathological features in gastric adenocarcinoma.

Guoyu Huang1, Feifei Cui1, Fudong Yu1, Huijun Lu2, Meng Zhang2, Huamei Tang2, Zhihai Peng3.   

Abstract

BACKGROUND: Several members of the SIRT family (SIRT1-7), which are a highly conserved family of NAD(+)-dependent enzymes, play an important role in tumor formation. Recently, several studies have suggested that SIRT4 can regulate glutamine metabolism yet have tumor suppressor function too. However, our understanding of SIRT4 expression and its association with the clinicopathological parameters remains poor.
METHOD: We evaluated SIRT4 protein expression levels in gastric adenocarcinoma and corresponding normal gastric tissue by immunohistochemical staining on a tissue microarray that included 75 gastric adenocarcinoma patients. We also determined the association between SIRT4 expression levels and selected clinicopathological parameters in gastric adenocarcinoma.
RESULTS: We found that the expression level of SIRT4 in gastric adenocarcinoma was significantly lower than the corresponding normal tissue levels (P=0.003). Besides, lower SIRT4 levels were observed in pathological grade (P=0.002), depth of tumor invasion (P=0.034), positive lymph node numbers (P=0.005) and UICC stage (P=0.002).
CONCLUSIONS: Our results support the notion that SIRT4 behaves as a tumor suppressor at the human tissue protein level. In addition, our data indicate that SIRT4 might be closely involved in the process of gastric adenocarcinoma development and it might potentially serve as a diagnostic biomarker and therapeutic target in gastric adenocarcinoma.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Carcinogenesis; Gastric adenocarcinoma; SIRT4

Mesh:

Substances:

Year:  2015        PMID: 26054687     DOI: 10.1016/j.biopha.2015.04.013

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  16 in total

Review 1.  Protein lipoylation: an evolutionarily conserved metabolic regulator of health and disease.

Authors:  Elizabeth A Rowland; Caroline K Snowden; Ileana M Cristea
Journal:  Curr Opin Chem Biol       Date:  2017-11-21       Impact factor: 8.822

Review 2.  Mitochondrial Function, Metabolic Regulation, and Human Disease Viewed through the Prism of Sirtuin 4 (SIRT4) Functions.

Authors:  Cora N Betsinger; Ileana M Cristea
Journal:  J Proteome Res       Date:  2019-04-08       Impact factor: 4.466

3.  SIRT4 functions as a tumor suppressor during prostate cancer by inducing apoptosis and inhibiting glutamine metabolism.

Authors:  Zhuhui Ge; Yunqiu Xu; Guohao Cai; Liangliang Cai; Pingliang Sun; Guoyu Huang
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

Review 4.  Mitochondrial Sirtuins in Cancer: Emerging Roles and Therapeutic Potential.

Authors:  Jasmine George; Nihal Ahmad
Journal:  Cancer Res       Date:  2016-04-20       Impact factor: 12.701

5.  SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway.

Authors:  L Fu; Q Dong; J He; X Wang; J Xing; E Wang; X Qiu; Q Li
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

Review 6.  Intracellular Mono-ADP-Ribosylation in Signaling and Disease.

Authors:  Mareike Bütepage; Laura Eckei; Patricia Verheugd; Bernhard Lüscher
Journal:  Cells       Date:  2015-09-25       Impact factor: 6.600

7.  Association of sirtuins with clinicopathological parameters and overall survival in gastric cancer.

Authors:  Xiaobing Shen; Pengfei Li; Yuchao Xu; Xiaowei Chen; Haixiang Sun; Ying Zhao; Mengqi Liu; Wenwen Zhang
Journal:  Oncotarget       Date:  2017-09-08

Review 8.  Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer.

Authors:  Guoyu Huang; Guanbao Zhu
Journal:  Onco Targets Ther       Date:  2018-06-11       Impact factor: 4.147

9.  Knockout of SIRT4 decreases chemosensitivity to 5-FU in colorectal cancer cells.

Authors:  Yuanyuan Zhu; Guangyu Wang; Xiaobo Li; Tianzhen Wang; Mingjiao Weng; Yanqiao Zhang
Journal:  Oncol Lett       Date:  2018-05-31       Impact factor: 2.967

10.  SIRT4 acts as a tumor suppressor in gastric cancer by inhibiting cell proliferation, migration, and invasion.

Authors:  Hongjie Sun; Dongli Huang; Guozheng Liu; Fengguo Jian; Jianfang Zhu; Lixia Zhang
Journal:  Onco Targets Ther       Date:  2018-07-10       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.